Table 1 Main characteristics of all studies included in the meta-analysis
Study | Country | Sample/Female | Treatment | Colon/rectum (n) | Lymph node metastasis (no/yes, n) | Tumor size (cm) : (n) | TNM stage | Follow-up in months | S100A4 assay | Cut-off for high expression | High S100A4 expression: n (%) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gongoll, 2002 [17] | Germany | 709/296 | Surgery | 318/391 | 606/103 | <2: 42 2–5: 440 >5: 227 | I/II: 218 | NR | IHC | > 50% cancer cells stained | 114 (16.1) | OS, Clinicopathological parameters |
III/IV: 491 | ||||||||||||
Boye, 2010 [21] | Norway | 242/110 | Mixed | 163/79 | 185/57 | NR | I/II: 165 | Median 109, range 98–120 | IHC | Nuclear cancer cells staining positive | 73 (30.2) | OS, DFS |
III: 77 | ||||||||||||
Kwak, 2010 [22] | South Korea | 127/51 | Surgery | 55/72 | 73/54 | NR | I/II: 73 | Median 58.7, range 1.1-101.8 | IHC | 20% of tumor cells stained | 45 (35.4) | OS, Clinicopathological parameters |
III/IV: 54 | ||||||||||||
Wang, 2010 [23] | China | 115/52 | Surgery | 77/38 | 97/18 | NR | NR | Median 62, range 4-76 | IHC | ≥ 20% tumor cells stained | 66 (57.4) | OS, Clinicopathological parameters |
Huang, 2011 [24] | China | 112/53 | Surgery | 47/65 | 59/53 | ≤5: 74; >5: 38 | I/II: 57 | NR | IHC | > 35% cancer cells stained | 57 (50.9) | OS, Clinicopathological parameters |
III/IV: 55 | ||||||||||||
Kang, 2012 [26] | Korea | 526/204 | Surgery | 321/205 | 255/271 | NR | NR | Median 40.1, range 2–69 | IHC | 30% of tumor cells stained, | 136 (25.9) | OS, Clinicopathological parameters |
Kho, 2012 [27] | Australia | 409/159 | Mixed | 451/0 | NR | < 5: 205 ≥ 5: 204 | I/II: 256 | Median 34.6, range 0.4-351 | IHC | ≥ 50% cancer cells stained | 45 (11.0) | OS, Clinicopathological parameters |
III/IV: 133 | ||||||||||||
Lee, 2013 [29] | Korea | 333/144 | Surgery | NR | 240/93 | NR | I/II: 187 | At least 5Â years | IHC | Stained cells were grade one | 267 (50.0) | OS, DFS, Clinicopathological parameters |
III/IV:146 | ||||||||||||
Stein, 2011 [25] | Germany | 375/205 | Mixed | 185/190 | 341/34 | NR | I/II: 139 | Median 24.3 | RT-PCR | 0.387 S100A4 | 143 (49.7) | DFS |
III/IV: 61 | mRNA expression,% calibrator | |||||||||||
Cho, 2005 [18] | South Korea | 124/NR | Surgery | NS | 59/65 | <5: 57 | NR | Rang 14–38 | IHC | > 30% cancer cells stained | 69 (55.6) | Clinicopathological parameters |
≥ 5: 67 | ||||||||||||
Hemandas, 2006 [19] | Singapore | 54/23 | Mixed | 34/20 | 46/8 | <2: 5 | NR | Median 65, rang 3– 104 | IHC | > 20% cancer cells stained | 28 (51.9) | Clinicopathological parameters |
2-5: 31 >5: 18 | ||||||||||||
Kim, 2009 [20] | Korea | 73/40 | Surgery | 38/35 | 65/8 | ≤ 2: 4 | NR | NR | IHC | > 20% cancer cells stained | 40 (54.8) | Clinicopathological parameters |
2-5: 38 | ||||||||||||
≥ 5: 31 | ||||||||||||
Giraldez, 2013 [28] | Spain | 228/95 | CHT | 228/0 | NR | NR | II: 78 | Median 42, | RT-PCR | Risk score: 4.076 | NR | Clinicopathological parameters |
III: 150 | Range 6–152 |